Business
Pandox AB (publ) notes receipt of competition clearance and court hearing date for the acquisition of Dalata Hotel Group plc
Pandox AB (publ) notes receipt of competition clearance and court hearing date for the acquisition of Dalata Hotel Group plc
About this update from Pandox Ab Class B
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED, OR OTHERWISE WOULD CONTRAVENE APPLICABLE REGULATIONS IN SUCH JURISDICTION.On 15 July 2025, Pandox AB (publ) (“Pandox”) and Eiendomsspar AS (“Eiendomsspar”) announced, through Pandox Ireland Tuck Limited (“Bidco”), that Dalata Hotel Group plc (“Dalata”) and Bidco had agreed the terms of a recommended acquisition for the entire issued and to be issued share capital of Dalata (the “Acquisition”) by means of a Court-sanctioned scheme of arrangement under the Irish Companies Act 2014 (“Scheme”).On 12 August 2025, a scheme document containing details of the Acquisition and the notices convening the shareholder meetings to approve the Scheme was mailed to Dalata shareholders (the “Scheme Document”).On 11 September 2025, Dalata announced that its shareholders had voted in favour of all resolutions at each of the shareholder meetings.Pandox is pleased to announce that it has been notified it has received clearance from the EU Commission for the Acquisition, which is a major step towards completion of the Acquisition. Furthermore, a sanction hearing date for the Scheme, at the High Court of Ireland, has been set for 29 October 2025.Subject to satisfaction or waiver of the other Conditions set out in the Scheme Document, including the sanction by the Court of the Scheme at the Court Hearing, the Effective Date of the Scheme and closing of the transaction is expected to be early November 2025.Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meaning as given to them in the Scheme Document.EnquiriesGoodbody (Financial Adviser to the Consortium)Finbarr GriffinAndrew HackneyCameron DuncanJason MolinsWilliam HallPandoxLiia NõuSodali & Co (PR advisor)Seán LawlessEavan Gannon+353 (0)1 667 0400+46 8 506 205 50+353 (0) 85 116 7640+353 (0) 87 236 5973Irish Takeover Rules StatementsThe directors of Pandox (the “Pandox Directors”) accept responsibility for the information contained in this announcem...